CD40LG and autoimmune disease: Hence, the CD40–CD40L ICP represents an important therapeutic target in transplant therapy (33) and autoimmune diseases (34) as demonstrated by the large number of novel biologics being developed against it including those mentioned in the Introduction, such as letolizumab, dapirolizumab pegol, frexalimab, tegoprubart, TNX-1500, dazodalibep, or iscalimab.